Zefit Inc.

📌 Accelerating Preclinical Study with Zebrafish From your bench to preclinical study, ZEFIT streamlines the drug discovery process with high-throughput zebrafish models. As a Contract Research Organization (CRO) specializing in innovative zebrafish models, ZEFIT offers preclinical testing services to minimize the cost and duration of drug development. Our disease-specific zebrafish models, combined with automated lab facilities, enable precise, efficient, and optimized drug efficacy and toxicity testing. 📌 Cutting-Edge Zebrafish Models Using CRISPR-based genetic models (KO/KI), we have developed 21+ customized research models, covering diseases such as Alzheimer’s, Parkinson’s, and cancer. As proof of our expertise, we hold patents for our cancer and Alzheimer’s models and have established a Good Laboratory Practice (GLP)-level Standard Operating Procedure (SOP) for organ toxicity assessments. In January 2025, one of our partners received US FDA Orphan Drug Designation based on zebrafish experiment data generated at ZEFIT. 📌 A Global Preclinical Partner Located in Seoul & Daegu, South Korea, we provide zebrafish-based drug screening services worldwide. Our strong domestic foundation includes MOUs with major pharmaceutical companies and research partnerships with the Korea National Institute of Health. 📌 Innovation Through Automation We enhance lab precision, by integrating biology with AI-driven software automation, as well as robotics-based hardware automation. Our technology can reduce drug screening timelines by up to 1/20 and costs by 1/100 compared to traditional mouse models—maximizing efficiency and success rates. 🔬 Discover the future of preclinical drug screening. For more information, please visit www.zefit.co.kr/en. Keywords: #Zebrafish, #CRO, #preclinical testing service, #drug discovery, #drug efficacy, #drug toxicity, #automation, #HTS